Genetic Mutations Linked to Early-Onset Alzheimer’s Disease
Overview of Alzheimer’s Disease
Alzheimer’s Disease (AD) is recognized as the most prevalent form of dementia, although only a small percentage of patients experience early-onset Alzheimer’s Disease (EOAD). Recent discoveries have identified genetic mutations in specific genes associated with EOAD, which can be utilized in genetic counseling.
Key Genetic Factors in EOAD
Research has shown that mutations in the amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes are responsible for the hereditary forms of EOAD. Even though these genes were identified over two decades ago, investigations into their genetic variations and their implications for disease severity continue.
Recent Study Insights
A recent publication by Hélène-Marie Lanoiselée and colleagues in PLOS Medicine updates findings from a previous genetic screening study on EOAD. This study expanded upon earlier data gathered from 28 French hospitals and focused on 53 families with at least two first-degree relatives diagnosed with EOAD by the age of 65 across two generations. Additionally, the research analyzed 129 sporadic cases of Alzheimer’s disease, defined as instances without a prior familial history of EOAD, all of which had an age of onset below 51 years (44% males, mean age of onset = 45 ± 2 years).
Methodology and Findings
The researchers conducted a search for genetic mutations in the APP, PSEN1, and PSEN2 genes using Sanger sequencing on DNA samples obtained from whole blood. When combined with data from earlier studies, the analysis identified mutations in APP, PSEN1, and PSEN2 in 170 EOAD families. Notably, 18 sporadic cases revealed mutations in PSEN1 (17 cases) and APP (1 case). Furthermore, in 10 sporadic instances, genetic mutations were not present in the parents, indicating the occurrence of de novo mutations. The study uncovered a total of 90 distinct mutations, of which 13 were previously unreported.
Implications for Genetic Counseling
The findings provide a clearer understanding of how approximately 77% of these 90 mutations influence disease severity, enhancing their utility in genetic counseling. Importantly, a significant number of PSEN1 mutations were found in individuals without a familial history of EOAD, suggesting a need for broader screening practices. Currently, PSEN1 mutation screening is limited to patients with a family history of EOAD; thus, it is recommended that clinicians also consider patients with sporadic EOAD for genetic screening of APP, PSEN1, and PSEN2 genes.
Conclusion
The ongoing research into genetic mutations associated with early-onset Alzheimer’s disease is vital for improving genetic counseling and diagnosis. As our understanding evolves, it is essential to adapt screening practices to include a wider range of patients, ultimately enhancing care for those affected by this challenging condition.